Zenas Biopharma, Common Etf Performance
| ZBIO Etf | USD 8.33 0.19 2.23% |
The entity maintains a market beta of 0.098, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Zenas BioPharma,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Zenas BioPharma, is expected to be smaller as well.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Zenas BioPharma, is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 56.9 M |
Zenas |
Zenas BioPharma, Relative Risk vs. Return Landscape
If you would invest 975.00 in Zenas BioPharma, Common on December 24, 2024 and sell it today you would lose (142.00) from holding Zenas BioPharma, Common or give up 14.56% of portfolio value over 90 days. Zenas BioPharma, Common is currently does not generate positive expected returns and assumes 6.2501% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of etfs are less volatile than Zenas, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zenas BioPharma, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zenas BioPharma,'s investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as Zenas BioPharma, Common, and traders can use it to determine the average amount a Zenas BioPharma,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0118
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZBIO |
Estimated Market Risk
| 6.25 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Zenas BioPharma, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zenas BioPharma, by adding Zenas BioPharma, to a well-diversified portfolio.
Zenas BioPharma, Fundamentals Growth
Zenas Etf prices reflect investors' perceptions of the future prospects and financial health of Zenas BioPharma,, and Zenas BioPharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zenas Etf performance.
| Current Valuation | (95.13 M) | ||||
| Price To Book | 0.81 X | ||||
| Revenue | 5 M | ||||
| EBITDA | (163.89 M) | ||||
| Total Debt | 1 M | ||||
| Book Value Per Share | (21.07) X | ||||
| Cash Flow From Operations | (119.67 M) | ||||
| Total Asset | 369.97 M | ||||
| Retained Earnings | (387.39 M) | ||||
About Zenas BioPharma, Performance
By examining Zenas BioPharma,'s fundamental ratios, stakeholders can obtain critical insights into Zenas BioPharma,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Zenas BioPharma, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.| Zenas BioPharma, generated a negative expected return over the last 90 days | |
| Zenas BioPharma, has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 5 M. Net Loss for the year was (156.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| The fund created three year return of -33.0% | |
| Zenas BioPharma, Common keeps most of the net assets in exotic instruments. |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.